Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region

Yıl: 2020 Cilt: 31 Sayı: 2 Sayfa Aralığı: 148 - 155 Metin Dili: İngilizce DOI: 10.5152/tjg.2020.19440 İndeks Tarihi: 09-06-2021

Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region

Öz:
Background/Aims: Hepatitis C virus (HCV) infection is a common disease that causes liver cirrhosis, hepatocellular carcinoma, and extra hepatic manifestations with high mortality and morbidity rates. This study aimed to present real-life experiences and results of treatment of HCV infection with direct-acting antiviral agents (DAAs) from the Euro-Asian region, including Turkey and Azerbaijan.Materials and Methods: A total of 1224 patients with chronic HCV infection were treated with DAAs in accordance with the international guidelines for the management of HCV infection. The mean age was 58.74±14.75 years, with 713 (58.25%) females. The genotypes of the patients were as follows: genotype 1b, 83.36% (n=1024); genotype 1a, 8.08% (n=99); genotype 2, 2.85% (n=35); genotype 3, 3.34% (n=41); genotype 4, 1.71% (n=21); and combined genotypes, 0.32% (n=4). Approximately 808 patients were treated with sofosbuvir-based DAAs with or without Ribavirin for 12 or 24 weeks, whereas 416 patients were treated with the Paritaprevir, Ombitasvir, Ritonavir.Dasabuvir (PROD) regimen with or without Ribavirin for 12 weeks or 24 weeks.Results: At the end of follow-up examinations, 1183 patients (97.93%) had sustained virological response (SVR), 17 (1.40%) died of reasons unrelated to the treatment regimen, 12 had recurrence after treatment, and 129 (10.67%) had adverse events like anemia, itching, and weakness.Conclusion: In this large cohort of HCV-infected patients, treatment with DAAs yielded a high overall SVR rate of 97.93%. DAAs were safe and well-tolerated. Thus, the elimination of HCV infection is no longer a dream worldwide.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Younossi ZM, Tanaka A, Eguchi Y, et al. The impact of hepatitis C virus outside the liver: evidence from asia. Liver Int 2017; 37: 159-72.
  • 2. GBD 2013 Mortality and Causes of Death Collaborators. Global, region al, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 385: 117-71.
  • 3. European association for the study of the liver EASL clinical prac tice guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
  • 4. Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and lab oratory testing. Hepatol Int 2016; 10: 681-701.
  • 5. AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Rec-ommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2018; 67: 1477-92.
  • 6. Kowdley KV, Kowdley KV, Sundaram V, et al. Eight weeks of Ledi pasvir/Sofosbuvir is ef-fective for selected patients with genotype 1 hepatitis C virus infection. Hepatology 2017; 65: 1094-103.
  • 7. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and Sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
  • 8. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889- 98.
  • 9. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and Sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-888.
  • 10. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-World Effectiveness of Ledipasvir/ Sofosbuvir in 4,365 Treat ment-Naive, Genotype 1 Hepatitis C-Infected Patients. Hepatology 2016; 64: 405-14.
  • 11. Butt AA, Yan P, Shaikh OS, et al. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Int 2016; 36: 651-65.
  • 12. Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus Sofosbu vir, with or without Rib-avirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016; 65: 1861-70.
  • 13. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med 2014; 370: 1973-82.
  • 14. Ahmed H, Abushouk AI, Menshawy A, et al. Perspective managing adverse effects and complications in completing treatment for hep atitis C virus infection HCV Treatment Complications. J Infect Public Health 2018; 11: 156-64.
  • 15. Hsieh YC, Jeng WJ, Huang CH, et al. Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. PLoS One 2018; 13: e0202777.
  • 16. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-la bel, multicentre phase 3 trial. Lancet Infect Dis 2017; 17: 1062-8.
  • 17. Lim SG, Phyo WW, Shah SR, et al. Findings from a large Asian chronic hepatitis C real-life study. J Viral Hepat 2018; 25: 1533-42.
  • 18. Foster GR, Afdhal SK, Roberts SK, et al. Sofosbuvir and Velpat asvir for HCV Genotype 2 and 3 Infection. N Engl J Med 2015; 373: 2608-17.
  • 19. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014; 21: 762-8.
  • 20. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepa tol 2009; 51: 655-66.
  • 21. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepato-cellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011; 18: e516-22.
  • 22. Feld J J, Maan R, Zeuzem S, et al. Effectiveness and safety of Sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study. Clin Infect Dis 2016; 63: 776-83.
  • 23. Hezode C, Lebray P, Ledinghen VD, et al. Daclatasvir plus So fosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver Int 2017; 37: 1314-24.
  • 24. Berden FA, Aaldering BR, Groenewoud H, IntHout J, Kievit W, Drenth JP. Identification of the Best Direct-Acting Antiviral Regimen for Patients with Hepatitis C Virus Genotype 3 Infection: A System atic Review and Network Meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 349-59.
  • 25. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treat ment with daclatasvir plus Sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127-35.
  • 26. Shiha G, Esmat G, Hassany M, et al. Ledipasvir/Sofosbuvir with or without Ribavirin for 8 or 12 weeks for the treatment of HCV gen otype 4 infection: results from a randomized phase III study in Egypt. Gut 2019; 68: 721-8.
  • 27. Elsharkawy A, Fouad R, El Akel W, et al. Sofosbuvir-based treat ment regimens: real life results of 14 409 chronic HCV genotype 4 pa tients in Egypt. Aliment Pharmacol Ther 2017; 45: 681-7.
  • 28. Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus Sofos buvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther 2018; 47: 421-31.
  • 29. Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21 Suppl 1: 60-89.
  • 30. Mücke MM, Mücke VT, Lange CM, Zeuzem S. Special populations: treating hepatitis C in patients with decompensated cirrhosis and/ or advanced renal impairment. Liver Int 2017; 37: 19-25.
APA Örmeci N, Gulsen M, Sezgin O, Aghayeva S, Demir M, Koksal I, GÜNER R, Erarslan E, ASİLLER Ö, Balkan A, Yaraş S, ÇALISKAN KARTAL A (2020). Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. , 148 - 155. 10.5152/tjg.2020.19440
Chicago Örmeci Necati,Gulsen Murat Taner,Sezgin Orhan,Aghayeva Sevda,Demir Mehmet,Koksal Iftihar,GÜNER RAHMET,Erarslan Elife,ASİLLER Özgün Ömer,Balkan Ayhan,Yaraş Serkan,ÇALISKAN KARTAL AYSUN Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. (2020): 148 - 155. 10.5152/tjg.2020.19440
MLA Örmeci Necati,Gulsen Murat Taner,Sezgin Orhan,Aghayeva Sevda,Demir Mehmet,Koksal Iftihar,GÜNER RAHMET,Erarslan Elife,ASİLLER Özgün Ömer,Balkan Ayhan,Yaraş Serkan,ÇALISKAN KARTAL AYSUN Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. , 2020, ss.148 - 155. 10.5152/tjg.2020.19440
AMA Örmeci N,Gulsen M,Sezgin O,Aghayeva S,Demir M,Koksal I,GÜNER R,Erarslan E,ASİLLER Ö,Balkan A,Yaraş S,ÇALISKAN KARTAL A Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. . 2020; 148 - 155. 10.5152/tjg.2020.19440
Vancouver Örmeci N,Gulsen M,Sezgin O,Aghayeva S,Demir M,Koksal I,GÜNER R,Erarslan E,ASİLLER Ö,Balkan A,Yaraş S,ÇALISKAN KARTAL A Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. . 2020; 148 - 155. 10.5152/tjg.2020.19440
IEEE Örmeci N,Gulsen M,Sezgin O,Aghayeva S,Demir M,Koksal I,GÜNER R,Erarslan E,ASİLLER Ö,Balkan A,Yaraş S,ÇALISKAN KARTAL A "Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region." , ss.148 - 155, 2020. 10.5152/tjg.2020.19440
ISNAD Örmeci, Necati vd. "Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region". (2020), 148-155. https://doi.org/10.5152/tjg.2020.19440
APA Örmeci N, Gulsen M, Sezgin O, Aghayeva S, Demir M, Koksal I, GÜNER R, Erarslan E, ASİLLER Ö, Balkan A, Yaraş S, ÇALISKAN KARTAL A (2020). Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turkish Journal of Gastroenterology, 31(2), 148 - 155. 10.5152/tjg.2020.19440
Chicago Örmeci Necati,Gulsen Murat Taner,Sezgin Orhan,Aghayeva Sevda,Demir Mehmet,Koksal Iftihar,GÜNER RAHMET,Erarslan Elife,ASİLLER Özgün Ömer,Balkan Ayhan,Yaraş Serkan,ÇALISKAN KARTAL AYSUN Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turkish Journal of Gastroenterology 31, no.2 (2020): 148 - 155. 10.5152/tjg.2020.19440
MLA Örmeci Necati,Gulsen Murat Taner,Sezgin Orhan,Aghayeva Sevda,Demir Mehmet,Koksal Iftihar,GÜNER RAHMET,Erarslan Elife,ASİLLER Özgün Ömer,Balkan Ayhan,Yaraş Serkan,ÇALISKAN KARTAL AYSUN Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turkish Journal of Gastroenterology, vol.31, no.2, 2020, ss.148 - 155. 10.5152/tjg.2020.19440
AMA Örmeci N,Gulsen M,Sezgin O,Aghayeva S,Demir M,Koksal I,GÜNER R,Erarslan E,ASİLLER Ö,Balkan A,Yaraş S,ÇALISKAN KARTAL A Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turkish Journal of Gastroenterology. 2020; 31(2): 148 - 155. 10.5152/tjg.2020.19440
Vancouver Örmeci N,Gulsen M,Sezgin O,Aghayeva S,Demir M,Koksal I,GÜNER R,Erarslan E,ASİLLER Ö,Balkan A,Yaraş S,ÇALISKAN KARTAL A Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turkish Journal of Gastroenterology. 2020; 31(2): 148 - 155. 10.5152/tjg.2020.19440
IEEE Örmeci N,Gulsen M,Sezgin O,Aghayeva S,Demir M,Koksal I,GÜNER R,Erarslan E,ASİLLER Ö,Balkan A,Yaraş S,ÇALISKAN KARTAL A "Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region." Turkish Journal of Gastroenterology, 31, ss.148 - 155, 2020. 10.5152/tjg.2020.19440
ISNAD Örmeci, Necati vd. "Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region". Turkish Journal of Gastroenterology 31/2 (2020), 148-155. https://doi.org/10.5152/tjg.2020.19440